CN114107559A - 分析病毒来源治疗剂的方法 - Google Patents

分析病毒来源治疗剂的方法 Download PDF

Info

Publication number
CN114107559A
CN114107559A CN202111246733.XA CN202111246733A CN114107559A CN 114107559 A CN114107559 A CN 114107559A CN 202111246733 A CN202111246733 A CN 202111246733A CN 114107559 A CN114107559 A CN 114107559A
Authority
CN
China
Prior art keywords
sequence
viral
virus
sequencing
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111246733.XA
Other languages
English (en)
Chinese (zh)
Inventor
T·L·布罗特
M·D·哈里奇
W·T·巴德
G·A·迈耶斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American International Biotechnology LLC
United States Department of Health and Human Services
Original Assignee
American International Biotechnology LLC
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American International Biotechnology LLC, United States Department of Health and Human Services filed Critical American International Biotechnology LLC
Publication of CN114107559A publication Critical patent/CN114107559A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301—Endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/319—Exonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202111246733.XA 2015-07-31 2016-07-29 分析病毒来源治疗剂的方法 Pending CN114107559A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199663P 2015-07-31 2015-07-31
US62/199,663 2015-07-31
CN201680045182.1A CN108026567B (zh) 2015-07-31 2016-07-29 分析病毒来源治疗剂的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680045182.1A Division CN108026567B (zh) 2015-07-31 2016-07-29 分析病毒来源治疗剂的方法

Publications (1)

Publication Number Publication Date
CN114107559A true CN114107559A (zh) 2022-03-01

Family

ID=56682276

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111246733.XA Pending CN114107559A (zh) 2015-07-31 2016-07-29 分析病毒来源治疗剂的方法
CN201680045182.1A Active CN108026567B (zh) 2015-07-31 2016-07-29 分析病毒来源治疗剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680045182.1A Active CN108026567B (zh) 2015-07-31 2016-07-29 分析病毒来源治疗剂的方法

Country Status (5)

Country Link
US (1) US10662464B2 (cg-RX-API-DMAC7.html)
EP (1) EP3329013B1 (cg-RX-API-DMAC7.html)
JP (1) JP6907202B2 (cg-RX-API-DMAC7.html)
CN (2) CN114107559A (cg-RX-API-DMAC7.html)
WO (1) WO2017023782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3307878T3 (da) 2015-06-10 2021-10-11 Us Health Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger
CN109280700B (zh) * 2018-09-17 2022-04-12 上海海洋大学 精确测定中华绒螯蟹线粒体全基因组序列的方法
CN110923359A (zh) * 2019-11-29 2020-03-27 中国食品药品检定研究院 检测ⅰ型脊灰减毒活疫苗核酸突变的质谱检测引物组及其方法
EP3892737A1 (en) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2021243333A2 (en) * 2020-05-29 2021-12-02 Biohsv Holdings, Inc. Mass nucleic acid testing
CN114067907B (zh) * 2020-07-31 2022-07-08 普瑞基准生物医药(苏州)有限公司 一种准确鉴定rna病毒基因组变异的方法
CN114075596A (zh) * 2020-08-12 2022-02-22 深圳华大因源医药科技有限公司 一种基于高通量测序技术检测目的微生物基因组rna的方法
CN112646859B (zh) * 2020-12-30 2022-04-26 中国人民解放军疾病预防控制中心 一种基于宏基因组学的呼吸道咽拭子样本的建库方法和病原检测方法
CN113722162B (zh) * 2021-08-17 2025-02-14 大连海天兴业科技有限公司 Mvb网卡稳定性测试系统、方法及存储介质

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728519A (en) * 1990-11-06 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services Assay for virulent revertants of attenuated live vaccines and kits therefor
CN1239512A (zh) * 1997-08-07 1999-12-22 奥尔特威尔生物技术公司 脊髓灰质炎病毒具有复制能力的重组体萨宾i型株系
WO2014081937A2 (en) * 2012-11-21 2014-05-30 Duke University Oncolytic poliovirus for human tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4450642A3 (en) * 2008-01-17 2025-01-08 Sequenom, Inc. Single molecule nucleic acid sequence analysis processes and compositions
US8066983B2 (en) * 2008-03-14 2011-11-29 The Research Foundation Of State University Of New York Attenuated poliovirus
GB201213770D0 (en) * 2012-08-02 2012-09-12 Ucl Business Plc Screening methods
WO2016100812A1 (en) * 2014-12-19 2016-06-23 Moderna Therapeutics, Inc. Terminal modifications of polynucleotides
DK3307878T3 (da) 2015-06-10 2021-10-11 Us Health Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728519A (en) * 1990-11-06 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services Assay for virulent revertants of attenuated live vaccines and kits therefor
CN1239512A (zh) * 1997-08-07 1999-12-22 奥尔特威尔生物技术公司 脊髓灰质炎病毒具有复制能力的重组体萨宾i型株系
WO2014081937A2 (en) * 2012-11-21 2014-05-30 Duke University Oncolytic poliovirus for human tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEXANDER L. GRENINGER ET, AL.: "A Metagenomic Analysis of Pandemic Influenza A (2009 H1N1) Infection in Patients from North America", PLOS ONE, vol. 5, no. 10, pages 2 *
ALEXANDER NEVEROV ET, AL.: "Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines", PNAS, vol. 107, no. 46, pages 7 - 11 *

Also Published As

Publication number Publication date
WO2017023782A1 (en) 2017-02-09
US20180237835A1 (en) 2018-08-23
US10662464B2 (en) 2020-05-26
EP3329013A1 (en) 2018-06-06
CN108026567A (zh) 2018-05-11
JP6907202B2 (ja) 2021-07-21
EP3329013B1 (en) 2020-09-02
JP2018527948A (ja) 2018-09-27
CN108026567B (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
CN108026567B (zh) 分析病毒来源治疗剂的方法
US20250367278A1 (en) Variant strain-based coronavirus vaccines
US20220378904A1 (en) Hmpv mrna vaccine composition
JP2024513999A (ja) インフルエンザ-コロナウイルス組み合わせワクチン
WO2021222304A1 (en) Sars-cov-2 rna vaccines
JP2024514182A (ja) 呼吸器ウイルス組み合わせワクチン
WO2023283651A1 (en) Pan-human coronavirus vaccines
EP4355761A1 (en) Mrna vaccines encoding flexible coronavirus spike proteins
WO2023283642A2 (en) Pan-human coronavirus concatemeric vaccines
EP4355891A1 (en) Coronavirus glycosylation variant vaccines
US20250339508A1 (en) Therapeutic interfering particles for corona virus
EP3307878B1 (en) Processes for production and purification of nucleic acid-containing compositions
US11033617B2 (en) Duck hepatitis A virus type 3 mutant CH-P60-117C and construction thereof
Amexis et al. Sequence diversity of Jeryl Lynn strain of mumps virus: quantitative mutant analysis for vaccine quality control
KR101617142B1 (ko) 개선된 검출 정확성을 제공해 줄 수 있는 핵산검사 기반의 조류 인플루엔자 바이러스 검출 키트
KR102373570B1 (ko) 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
CN116144608A (zh) 病毒培养方法
Guirao et al. Phylogeny of canine coronavirus (CCoV) from Brazilian dogs based on membrane protein partial sequences
WO2025044471A1 (zh) 复制型逆转录病毒检测引物及方法
CN120225693A (zh) 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法
CZ33796U1 (cs) Primery pro sekvenaci části genomu viru šarky švestky za účelem stanovení kmenu viru a jeho případných mutací
Grywalski Towards in silico IBV vaccine design: defining the role of polymorphism in viral attenuation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220301

WD01 Invention patent application deemed withdrawn after publication